BioCentury | May 9, 2017
Distillery Techniques

Biomarkers

...Berlin, Germany email: lehrach@molgen.mpg.de CONTACT: Marie-Laure Yaspo, Max Planck Institute for Molecular Genetics, Berlin, Germany email: yaspo@molgen.mpg.de Hongjiang Li Alacris Theranostics GmbH Bayer AG Max Planck Institute for Molecular Genetics BRAF EGFR K-Ras...
BioCentury | Dec 3, 2012
Company News

Alacris Theranostics, GlaxoSmithKline deal

...mutation and drug databases to make a "virtual patient" model. ModCell was developed at the Max Planck Institute for Molecular Genetics...
BioCentury | Apr 23, 2012
Company News

Massachusetts General Hospital autoimmune news

...MassGeneral Institute for Neurodegenerative Disease (MIND); the not-for-profit Accelerated Cure Project for MS; and the Max Planck Institute for Molecular Genetics...
BioCentury | Mar 21, 2011
Company News

AstraZeneca, Bayer, Boehringer Ingelheim, J&J, Merck KGaA, Pfizer, Roche diagnostic news

...systematic next generation cancer biomarker development, with a focus on colon cancer. Bayer and the Max Planck Institute for Molecular Genetics...
BioCentury | May 22, 2008
Distillery Therapeutics

This Week in Therapeutics

...al. Am. J. Hum. Genet.; published online May 1, 2008; doi:10.1016/j.ajhg.2008.03.018 Contact: Andreas Walter Kuss, Max Planck Institute for Molecular Genetics...
BioCentury | Apr 3, 2008
Distillery Techniques

This Week in Techniques

...Chen, W. et al. Genome Res.; published online March 7, 2008; doi:10.1101/gr.076166.108 Contact: Wei Chen, Max Planck Institute for Molecular Genetics...
BioCentury | Dec 6, 2004
Company News

Scienion, Max Planck Institute for Molecular Genetics deal

...production of screening arrays loaded with chemicals and active agents. Scienion AG , Berlin, Germany Max Planck Institute for Molecular Genetics...
BioCentury | Sep 13, 2004
Emerging Company Profile

Scienion: Market-driven chips

The biochip market is dominated by Affymetrix Inc. , but Scienion AG believes it has technology that doesn't step on AFFX's toes. The company is selling into the lucrative microbial research market niche, which it hopes...
BioCentury | Sep 13, 2004
Emerging Company Profile

Corporate Profile

Scienion AG Berlin, Germany Technology: Generic and customized microarrays Disease focus: N/A Clinical status: N/A Founded: 2000 by Holger Eickhoff, Martin Horn, Wilfried Nietfeld, Hans Lehrach, Sebastian Delbrueck and Heike Feldkort Corporate partners: Agowa GmbH;...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

...built out. When GPC Biotech AG was founded in 1997 as a spinout from the Max Planck Institute for Molecular Genetics...
...$74.8M (follow-on) Table: GPC timeline Selected asset-enhancing events. Date Asset 1997 Functional genomics technology from Max Planck Institute for Molecular Genetics...
...formerly NeoTherapeutics) 2004 $105.6M (rights offering and follow-on) Date Asset 1997 Functional genomics technology from Max Planck Institute for Molecular Genetics...
Items per page:
1 - 10 of 20
BioCentury | May 9, 2017
Distillery Techniques

Biomarkers

...Berlin, Germany email: lehrach@molgen.mpg.de CONTACT: Marie-Laure Yaspo, Max Planck Institute for Molecular Genetics, Berlin, Germany email: yaspo@molgen.mpg.de Hongjiang Li Alacris Theranostics GmbH Bayer AG Max Planck Institute for Molecular Genetics BRAF EGFR K-Ras...
BioCentury | Dec 3, 2012
Company News

Alacris Theranostics, GlaxoSmithKline deal

...mutation and drug databases to make a "virtual patient" model. ModCell was developed at the Max Planck Institute for Molecular Genetics...
BioCentury | Apr 23, 2012
Company News

Massachusetts General Hospital autoimmune news

...MassGeneral Institute for Neurodegenerative Disease (MIND); the not-for-profit Accelerated Cure Project for MS; and the Max Planck Institute for Molecular Genetics...
BioCentury | Mar 21, 2011
Company News

AstraZeneca, Bayer, Boehringer Ingelheim, J&J, Merck KGaA, Pfizer, Roche diagnostic news

...systematic next generation cancer biomarker development, with a focus on colon cancer. Bayer and the Max Planck Institute for Molecular Genetics...
BioCentury | May 22, 2008
Distillery Therapeutics

This Week in Therapeutics

...al. Am. J. Hum. Genet.; published online May 1, 2008; doi:10.1016/j.ajhg.2008.03.018 Contact: Andreas Walter Kuss, Max Planck Institute for Molecular Genetics...
BioCentury | Apr 3, 2008
Distillery Techniques

This Week in Techniques

...Chen, W. et al. Genome Res.; published online March 7, 2008; doi:10.1101/gr.076166.108 Contact: Wei Chen, Max Planck Institute for Molecular Genetics...
BioCentury | Dec 6, 2004
Company News

Scienion, Max Planck Institute for Molecular Genetics deal

...production of screening arrays loaded with chemicals and active agents. Scienion AG , Berlin, Germany Max Planck Institute for Molecular Genetics...
BioCentury | Sep 13, 2004
Emerging Company Profile

Scienion: Market-driven chips

The biochip market is dominated by Affymetrix Inc. , but Scienion AG believes it has technology that doesn't step on AFFX's toes. The company is selling into the lucrative microbial research market niche, which it hopes...
BioCentury | Sep 13, 2004
Emerging Company Profile

Corporate Profile

Scienion AG Berlin, Germany Technology: Generic and customized microarrays Disease focus: N/A Clinical status: N/A Founded: 2000 by Holger Eickhoff, Martin Horn, Wilfried Nietfeld, Hans Lehrach, Sebastian Delbrueck and Heike Feldkort Corporate partners: Agowa GmbH;...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

...built out. When GPC Biotech AG was founded in 1997 as a spinout from the Max Planck Institute for Molecular Genetics...
...$74.8M (follow-on) Table: GPC timeline Selected asset-enhancing events. Date Asset 1997 Functional genomics technology from Max Planck Institute for Molecular Genetics...
...formerly NeoTherapeutics) 2004 $105.6M (rights offering and follow-on) Date Asset 1997 Functional genomics technology from Max Planck Institute for Molecular Genetics...
Items per page:
1 - 10 of 20